TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31079535
Drug: Pegloticase (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase (8 mg every 2 weeks)
Study: 28962046
Drug: Sodium butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium butyrate capsules
Study: 28962046
Drug: Inulin supplement
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin supplement powder
Study: 19683825
Drug: Bed-time NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bed-time NPH insulin
Study: 15281501
Drug: Bupivacaine (0.125%;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Study: 15281501
Drug: Levobupivacaine (0.125%;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Study: 15281501
Drug: Ropivacaine (0.125%;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Study: 9990415
Drug: Tretinoin formulations
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin formulations (0.05% and 0.1%)
Study: 9990415
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel and cream
Study: 3415207
Drug: Moxalactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (2 g i.v. every 8 h for 5 doses, then 2 g every 12 h)
Study: 3415207
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg i.v. every 6 h) plus Gentamicin (1.5 mg/kg i.v. every 8 h)
Study: 27703346
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS)
Study: 25215556
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions (Z3P3, n = 617)
Study: 25215556
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of treatment after 3 years
Study: 18154091
Drug: 5-fluorouracil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil administration during skin plasty operation
Study: 12940804
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of indomethacin, prochlorperazine, and caffeine
Study: 10613779
Drug: Antibiotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatments
Study: 10613779
Drug: Various therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapies
Study: 9327254
Drug: Behavioral medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine intervention (6-week duration)
Study: 3468098
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin by mouth once daily for ten days
Study: 3468098
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin by mouth twice daily for ten days
Study: 3468098
Drug: Concomitantly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitantly administered theophylline
Study: 27234663
Drug: Weekly PST
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly PST (n=1465)
Study: 27234663
Drug: Monthly HQACM
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly HQACM (n=1457)
Study: 27234663
Drug: PST twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST twice weekly (n=118)
Study: 14682413
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 microg once daily
Study: 14682413
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast 10 mg once daily
Study: 8897759
Drug: 10 million
Normalized name: Interferon Alfa-2b 10 MILLION IU/1 ML Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 million units of IFN-alpha 2b daily for 2 weeks
Study: 8897759
Drug: 10 million
Normalized name: Interferon Alfa-2b 10 MILLION IU/1 ML Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 million units of IFN-alpha 2b twice a week for 24 weeks
Study: 26356548
Drug: RPA training
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPA training (leg-press exercise, twice a week for 6 weeks, 1 or 2 blocks of 5 sets × 5 repetitions with 20 s of passive recovery between sets and 3 min between blocks)
Study: 16350679
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation of fish oil (600 mg) with garlic pearls (500 mg) per day for 60 days
Study: 2570701
Drug: cetirizine diHCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine diHCl 10 mg
Study: 28957407
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment prior to RCT)
Study: 25986641
Drug: Health consultation
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health consultation involving a self-help manual, monthly prompts, and spirometry
Study: 23892341
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 250 mg (steroid group)
Study: 17197377
Drug: Immediate substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate substitution with lopinavir/ritonavir 400/100 mg bid
Study: 1926985
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg bid)
Study: 6126170
Drug: THIP (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: THIP (10 to 25 mg single dose; 20 to 120 mg daily for four weeks)
Study: 29341471
Drug: Maximal tolerated
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tolerated dose of valsartan (titrated up to 320 mg/day, n=333)
Study: 29341471
Drug: Low-dose valsartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valsartan (80 mg/day, n=162)
Study: 29341471
Drug: Maximal tolerated
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tolerated dose of valsartan (titrated up to 320 mg/day)
Study: 29341471
Drug: Low-dose valsartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valsartan (80 mg/day)
Study: 22174029
Drug: Atomoxetine (Atx)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (Atx) 80 mg daily for 12 weeks
Study: 10084468
Drug: Ipratropium plus
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium plus Albuterol
Study: 10084468
Drug: Ipratropium plus
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium plus Albuterol and Ipratropium
Study: 7604808
Drug: Acute alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute alcohol consumption (70 g of ethanol diluted to 20% with lemonade)
Study: 2195934
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg three times per day for 14 days
Study: 22766970
Drug: Fractional CO(2)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO(2) laser treatments (3 monthly sessions, MedArt 610; 12-14 W, 48-56 mJ/pulse, 13% density)
Study: 12016098
Drug: Theophylline (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (plasma level of 9-11 mg/L) for 4 weeks
Study: 346628
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (cat pelt extract)
Study: 31362784
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg per day)
Study: 27632069
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (LR; placebo)
Study: 27632069
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) use
Study: 26502867
Drug: Casperome® 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casperome® 500 mg/day
Study: 23810644
Drug: Topiramate, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate, 300 mg daily
Study: 21543963
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g total dietary fiber per day from psyllium
Study: 21543963
Drug: Steady dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady dose segment (all fiber sources)
Study: 17456571
Drug: Cabergoline (Cb2)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (Cb2) 0.5 mg/d
Study: 29519777
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) for 14 weeks (n=117)
Study: 29519777
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n=122)
Study: 26338889
Drug: Dal (lentils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dal (lentils enriched to 85.1% with (57)Fe, 8 mg native (57)Fe)
Study: 26338889
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (7 mg FeSO4 plus 1 mg (58)Fe)
Study: 8427539
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 or 1000 mg daily (n = 21)
Study: 8427539
Drug: Clarithromycin 1500
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 1500 or 2000 mg daily (n = 56)
Study: 8427539
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with clarithromycin
Study: 8427539
Drug: Stopped treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped treatment for 7 days or longer
Study: 8427539
Drug: Concomitant AIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant AIDS drugs
Study: 24299021
Drug: Montelukast treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast treatment for 3 months
Study: 14509153
Drug: Garlic (alliin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (alliin 22.4 mg/day)
Study: 7590497
Drug: Desferrioxamine (DFO)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFO) at a dose of 40 mg/kg/day as a 24-hour intravenous infusion from day -9 to day +60
Study: 2671247
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional insulin treatment (ICT)
Study: 1101904
Drug: Chlordiazepoxide 10
Normalized name: chlordiazepoxide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide 10 mg t.i.d.
Study: 1101904
Drug: Flupenthixole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixole 0.5 mg t.i.d.
Study: 1101904
Drug: Chlordiazepoxide with
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlordiazepoxide with alcohol (0.5 g/kg)
Study: 1101904
Drug: Flupenthixole with
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixole with alcohol (0.5 g/kg)
Study: 30829050
Drug: OTO-201 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTO-201 (0.2 mL, 12 mg, n = 130)
Study: 30829050
Drug: Sham (air
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (air injection, n = 130)
Study: 24254557
Drug: 1 cc
Normalized name: BD Needle SG 1 cc 27g 5/8"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cc 1% lidocaine before biopsy
Study: 21270143
Drug: Oral antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic regimen selected by control patient's psychiatrist
Study: 19091331
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg selenium orally daily (selenium group of 116)
Study: 19091331
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg N-acetyl-cysteine orally daily (N-acetyl-cysteine group of 118)
Study: 19091331
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg selenium plus 600 mg N-acetyl-cysteine orally daily (selenium plus N-acetyl-cysteine group of 116)
Study: 11310696
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of blood products through central venous catheters
Study: 3773728
Drug: 30 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 IU/kg heparin
Study: 20562076
Drug: 50 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg heparin
Study: 3773728
Drug: 75 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU/kg heparin
Study: 3773728
Drug: 100 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/kg heparin
Study: 3773728
Drug: Repeated daily
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated daily injections of 75 IU/kg heparin
Study: 3773728
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of heparin or saline on three consecutive days
Study: 26963689
Drug: Aripiprazole (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Study: 26963689
Drug: Placebo (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Study: 20386995
Drug: Double-blind cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind cyclical alternative medications for osteoarthritis
Study: 20386995
Drug: Double-blind cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind cyclical alternative medications for chronic neuropathic pain
Study: 20386995
Drug: Double-blind cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind cyclical alternative medications for ADHD
Study: 18469572
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 800 microg
Study: 18469572
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 400 microg
Study: 18469572
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 200 microg
Study: 18320340
Drug: Short-term desmopressin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term desmopressin (0.2 mg for first 3 weeks, 0.4 mg for following 3 weeks) plus 12 weeks of enuretic alarm therapy
Study: 18320340
Drug: Enuretic alarm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enuretic alarm therapy alone for 12 weeks
Study: 18320340
Drug: Short-term desmopressin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term desmopressin plus alarm therapy
Study: 15029120
Drug: Antibacterial drug
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial drug treatment with sumamed
Study: 15029120
Drug: Antibacterial drug
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial drug treatment with rulid
Study: 15029120
Drug: Antibacterial drug
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial drug treatment with clindamycin
Study: 24734423
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (mature infants)
Study: 24734423
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (premature infants)
Study: 24734423
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (mature infants)
Study: 24734423
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (premature infants)
Study: 21788265
Drug: Short-term practice
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term practice group (1 treatment protocol over 4 weeks)
Study: 19326288
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg prolonged-release preparation, CircadinTM)
Study: 15619134
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (130 mg twice daily for 3 days)
Study: 11703885
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg extended-release daily
Study: 11703885
Drug: Tolterodine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (various doses)
Study: 11703885
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg tid
Study: 8484548
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction followed by propofol infusion and nitrous oxide (Group 2)
Study: 3547179
Drug: Diacereine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacereine (100 mg/die for 4 weeks)
Study: 3547179
Drug: Diacereine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacereine (100 mg/die for 2 weeks)
Study: 3547179
Drug: Diacereine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacereine (100 mg/die 5 days a week for 12 weeks)
Study: 27531238
Drug: Hybrid of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid of intracavitary and interstitial brachytherapy (HBT) with 30‐30.6 Gy in 15‐17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP (40 mg/m(2)), followed by 24 Gy in 4 fractions of HBT and central shield EBRT up to 50‐50.4 Gy in 25‐28 fractions.
Study: 18655753
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution; n = 32)
Study: 16428155
Drug: Butenafine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butenafine once daily for 2 weeks
Study: 16428155
Drug: Clotrimazole twice
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole twice daily for 4 weeks
Study: 12114432
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1250 mg/m2 on days 1 and 8 every 3 weeks
Study: 2351364
Drug: Neurotropin tablets
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropin tablets
Study: 385518
Drug: V. F.
Normalized name: Vancomycin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: V. F. (peptides from bovine Factor VIII) administered at 1 mg/day in two oral doses
Study: 25500935
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Cortef (glucocorticoids) administered orally in the late afternoon for 6 days
Study: 17117395
Drug: memantine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (titrated to 20 mg)
Study: 15569113
Drug: Pantoprazole (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (10, 20, or 40 mg daily)
Study: 15569113
Drug: Pantoprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (20 or 40 mg daily)
Study: 15569113
Drug: Nizatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (150 mg b.d.)
Study: 8002638
Drug: UFT (uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (uracil and tegafur) 400 mg/day for 1 year
Study: 2790692
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + RT (Continuous 5-FU infusion followed by hepatic irradiation of 25.5 Gy)
Study: 2790692
Drug: CT (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Continuous 5-FU infusion)
Study: 801578
Drug: Fentanyl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1 mg reinjection)
Study: 801578
Drug: Sulfentanil (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfentanil (0.01 mg reinjection)
Study: 801578
Drug: Fentanyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.5 mg reinjection)
Study: 801578
Drug: Sulfentanil (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfentanil (0.05 mg reinjection)
Study: 801578
Drug: Fentanyl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1 mg reinjection) with droperidol (1.25 mg)
Study: 801578
Drug: Sulfentanil (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfentanil (0.01 mg reinjection) with droperidol (1.25 mg)
Study: 17903073
Drug: Combined continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined continuous ethinyl estradiol (10 microg) and norethindrone acetate (1 mg) given once daily for 3 months
Study: 16131023
Drug: Yogurt supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt supplementation (125 g, 5 days a week for 9 months)
Study: 1942990
Drug: bemitil (0.25‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bemitil (0.25‐0.5 g/day orally for 5‐7 days)
Study: 7452507
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day p.o.)